Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir

Phase 2

BRAIN Biotech AG (BNN.DE)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

BNN.DEPhase 2$66M

Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir Phase 2 Est. Readout

Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir• Leptomeningeal Metastasis of Breast Cancer22

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Leptomeningeal Metastasis of Breast Cancer

View Full Landscape

Drug Information

Target Indication

Leptomeningeal Metastasis of Breast Cancer

Clinical Trial

NCT06543992

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BNN.DE

BRAIN Biotech AG

Pharmaceutical Preparations•Europe•Xetra

Related Pipeline

Celecoxib 400mgPhase 3

Depressive Disorder, Major

ProgesteronePhase 3

Alcohol Dependence

INS-GSHPhase 2

Parkinson Disease

EtidronatePhase 2

Fahr Disease

0.5 mgTestosterone + 10 mg BuspironePhase 2

Hypoactive Sexual Desire Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts